CEVR analyzes the value of strategies to improve health and health care.

About Us

News & Events

First look at US commercial health payers’ coverage of Amjevita™ shows Humira® remaining on top—at least for now

By Fariel LaMountain, BA, Molly T. Beinfeld, MPH, and James D. Chambers, PhD, MPharm, MSc September 12, 2023 Introduction The introduction of Amgen’s ...

Read more September 12, 2023
New CEVR publication: Turning CMS into a Health Technology Assessment Organization

Journal: The New England Journal of Medicine Citation: Neumann PJ, Tunis SR. Turning CMS into a health technology assessment organization. N Engl J Me...

Read more August 25, 2023
How US commercial health plans are covering semaglutide (Wegovy®) for obesity management

By Daniel Enright, MS, Molly T. Beinfeld, MPH, and James D. Chambers, PhD, MPharm, MSc August 17, 2023 Introduction Two years after its approval, ques...

Read more August 17, 2023
View All News & Events

Recent Publications

The Milbank Quarterly
Improving Food and Drug Administration–Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval
View publication
August 29, 2023
Journal of Managed Care and Specialty Pharmacy
Specialty drug coverage varies between health plans’ medical and pharmacy benefit policies
View publication
June 5, 2023
BioDrugs
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans
View publication
April 1, 2023
Value in Health
Developing Criteria for Health Economic Quality Evaluation Tool
View publication
April 15, 2023
STAT News First Opinion
The much-maligned ‘quality-adjusted life year’ is a vital tool for health care policy
View publication
March 22, 2023
Health Affairs Forefront
Publication of Makena negative confirmatory trial had little impact on payer behavior
View publication
January 13, 2023
Journal of Managed Care + Specialty Pharmacy
Commercial health plans use of patient subgroup restrictions: An analysis of orphan and FDA-expedited programs
View publication
March 2, 2023
Alzheimer's & Dementia
Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease
View publication
February 28, 2023
Journal of Managed Care & Specialty Pharmacy
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions
View publication
February 27, 2023
Health Affairs Forefront
Options for CMS drug price negotiations
View publication
January 4, 2023
Patient Preference and Adherence
Patient and caregiver views on measures of the value of health interventions
View publication
December 20, 2022
Value in Health
The impact on cost-effectiveness of accounting for generic drug pricing: Four case studies
View publication
November 3, 2022
Applied Health Economics and Health Policy
Family spillover effects: Are economic evaluations misrepresenting the value of healthcare interventions to society?
View publication
August 23, 2022
Journal of Managed Care & Specialty Pharmacy
When are breakthrough therapies cost-effective?
View publication
July 28, 2022
JAMA Network Open
Racial and ethnic differences in hospice use and hospitalizations at end-of-life among Medicare beneficiaries with dementia
View publication
June 9, 2022
View All Publications

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.

CEA Registry

The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.

View Registry

Global Health CEA Registry

The GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.

View Registry

SPEC Database

The Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.

View Database
Learn About Our Databases